<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study reviews results of a radiation-free preparative regimen consisting of <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in 65 unrelated allogeneic bone marrow transplant recipients </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-eight patients had <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (17 patients <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, 13 patients accelerated phase, eight patients <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e>), 19 patients had <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (second complete remission or relapse) and eight patients had <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The patients were transplanted at four different medical centers from July 1988 to November 1992 </plain></SENT>
<SENT sid="3" pm="."><plain>Ages ranged 4-48 years (median 32) </plain></SENT>
<SENT sid="4" pm="."><plain>Fifty-seven patients received <z:chebi fb="0" ids="28901">busulfan</z:chebi> 16 mg/kg and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg, and eight received <z:chebi fb="0" ids="28901">busulfan</z:chebi> at doses between 15 and 17 mg/kg and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> at doses 100-200 mg/kg as preparative regimens </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis; in addition 46 patients received <z:chebi fb="0" ids="50858">corticosteroid</z:chebi>, 38 methotrexate, six anti-CD5 ricin A-immunotoxin, and four T cell-depleted bone marrow </plain></SENT>
<SENT sid="6" pm="."><plain>Median follow-up of survivors was 53 months (range 15-68 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Four year actuarial survival was 24 +/- 12% </plain></SENT>
<SENT sid="8" pm="."><plain>Four-year survival based on disease was 29 +/- 27% for <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, 20 +/- 9% for <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in accelerated phase, 0% for <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e>, 32 +/- 40% for <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, and 38 +/- 34% for <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Actuarial survival was 66 +/- 40% in patients age &lt; 20 years, vs 23 +/- 13% for patients ages 20 to 40, and 10 +/- 14% for patients age &gt; 40 years </plain></SENT>
<SENT sid="10" pm="."><plain>Fifty patients (88%) engrafted </plain></SENT>
<SENT sid="11" pm="."><plain>Graft failure occurred in eight patients </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> grade II-IV occurred in 36 (72%) </plain></SENT>
<SENT sid="13" pm="."><plain>Two patients relapsed after engraftment with the donor cells and died of <z:hpo ids='HP_0001909'>leukemia</z:hpo> within a month of relapse </plain></SENT>
<SENT sid="14" pm="."><plain>The most common causes of <z:hpo ids='HP_0011420'>death</z:hpo> were <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (37%), and transplant-related toxicity (59%); relapse (4%) was a rare cause of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain><z:chebi fb="0" ids="28901">Busulfan</z:chebi>/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> is an effective preparative regimen in unrelated bone marrow transplantation permitting adequate engraftment and a low relapse rate </plain></SENT>
<SENT sid="16" pm="."><plain>Best results are observed in patients less than 20 years old </plain></SENT>
</text></document>